10 January 2026
1 min read

Wesfarmers stock (ASX:WES) ends at A$81 — the next dates investors are circling

Wesfarmers stock (ASX:WES) ends at A$81 — the next dates investors are circling

Sydney, Jan 10, 2026, 17:24 AEDT — Market closed

  • Wesfarmers last traded at A$81.06 on Friday, up 0.12%.
  • The ASX 200 finished almost flat, with Rio Tinto’s slide offsetting gains in energy.
  • Inflation data due Jan 28 and Wesfarmers’ Feb 19 half-year results are next markers.

Wesfarmers Limited (WES.AX) shares ended Friday up 0.12% at A$81.06, a small lift ahead of Monday’s open on the Australian market.

The stock is a clean read on the household in Australia: a lot of shopping baskets, a lot of home projects. When rate expectations swing, retailers like Wesfarmers can get dragged with them, even without fresh company news.

That matters right now because the debate has shifted back to how long policy stays tight, not just when it loosens. Higher borrowing costs hit consumers first and they usually hit discretionary spend next.

The benchmark ASX 200 slipped 3 points to 8,716 on Friday after Rio Tinto fell 6.2%, leaving materials down 0.9% on the day even as energy gained 1.9%.

Wesfarmers traded between A$80.73 and A$81.71 on Friday, with about 1.04 million shares changing hands. The stock is inside a 52-week range of A$67.70 to A$95.18 and trades at about 31 times trailing earnings (its price-to-earnings ratio), market data showed. (StockAnalysis)

Kyle Rodda, a senior financial market analyst at Capital.com, said the prospect of Reserve Bank of Australia rate hikes is “a headwind” for parts of the market. He pointed to “underwhelming growth but high and possibly rising interest rates” as the problem mix, and noted the RBA’s cash rate — the benchmark that feeds into mortgage and business lending rates — is 3.6%. (Indo Premier)

Wesfarmers runs a mix of retail and industrial businesses, from Bunnings and Kmart to chemicals and a health division, which can soften the blows when one pocket of spending turns.

But the set-up cuts both ways. If inflation proves stubborn and borrowing costs rise again, shoppers can pull back fast, and the market can re-rate consumer stocks lower — meaning investors pay less for each dollar of profit.

The next big markers are on the calendar: the ABS is due to publish December CPI on Jan 28 and the RBA meets Feb 2–3, before Wesfarmers’ half-year results on Feb 19, where investors will look for updates on Bunnings sales, Kmart margins and costs. (Wesfarmers)

Stock Market Today

  • Vera Therapeutics Valuation Under Scrutiny After Momentum
    January 10, 2026, 5:06 PM EST. Vera Therapeutics (VERA) trades at $48.71 after a sharp rally, with a 1-month gain near 9.9% and a 3-month advance around 61.9% as investors weigh growth against clinical and financing risks. The 3-year total shareholder return runs about 7x. On a P/B of 8.7x, the stock sits above the broader US biotech average (2.7x) but below some peers (11.8x). A DCF view yields a fair value about $242.41, implying roughly an 80% discount to the current price. The company reports no revenue and a net loss of about $251.9 million. Upside depends on trial progress and funding; downside risk remains if milestones slip or financing deteriorates. Analysts' targets are higher than today's price, keeping a watchful eye on progress.
Zip Co stock ends week up 4% as traders turn to Feb results and US growth
Previous Story

Zip Co stock ends week up 4% as traders turn to Feb results and US growth

South32 stock near a 2026 high as dividend dates land; traders eye Feb 12 results
Next Story

South32 stock near a 2026 high as dividend dates land; traders eye Feb 12 results

Go toTop